Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart
Olaf
O
Cochrane Haematological Malignancies Group Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Street 62, D-50924 Cologne, Germany. olaf.weingart@uk-koeln.de
Rehan
Fareed A
FA
Schulz
Holger
H
Naumann
Frauke
F
Knauel
Ina
I
Bohlius
Corinne Brillant Julia
CB
Engert
Andreas
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab